CA-AXONICS
27.9.2018 12:02:03 CEST | Business Wire | Press release
Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that the Axonics r-SNM System was awarded the “Best Technological Innovation, Therapeutic Device” at the 2018 Medtech Insight Awards in partnership with the MedTech Conference being held this week in Philadelphia.
The Medtech Insight Awards highlight dedication and innovation within medical device and diagnostics, and the Axonics r-SNM System was recognized by the esteemed judging panel as “a major technological improvement in a validated market.”
“Axonics is honored by this recognition for the technological innovation of the Axonics r-SNM System,” said Raymond W. Cohen, Chief Executive Officer of Axonics. “This award is a testament to the diligence and ingenuity employed by our team over the last 4 years to develop and clinically validate a miniaturized, long-lived rechargeable SNM system.”
Axonics is currently conducting a pivotal study, ARTISAN-SNM, under an Investigational Device Exemption for urinary dysfunction designed to gain Food & Drug Administration (FDA) marketing approval in the United States upon completion of the study and review by the FDA. In June 2018, Axonics announced completion of enrollment for the pivotal study and expects all subjects to reach the 6-month primary endpoint at the end of 2018.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is a privately-held venture backed company that has developed a novel implantable neuromodulation technology for patients with urinary and bowel dysfunction. The Axonics r-SNM system is approved in the EU, Canada and Australia for the treatment of overactive bladder (urinary incontinence, urinary frequency), non-obstructive urinary retention and fecal incontinence. The Axonics system includes a miniaturized rechargeable implantable stimulator qualified to function at least 15 years, a charging system optimized for reduced charge time with no heating, a patient-friendly remote control and an intuitive clinician programmer that facilitates the lead placement procedure and programming. For more information, visit the Company’s website at www.axonicsmodulation.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180927005180/en/
Contact:
Company Contact Axonics Modulation Technologies, Inc. Dan Dearen, +1-949-396-6320 President & Chief Financial Officer ddearen@axonicsmodulation.com or Investor & Media Contact W2Opure Jill Bertotti, +1-714-225-6726 jbertotti@W2Ogroup.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 13:47:00 CEST | Press release
Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native
Kinaxis Convenes Global Supply Chain Leaders at Kinexions North America to Advance Agentic AI and Decision Orchestration28.5.2026 13:00:00 CEST | Press release
Annual conference brings customers, partners, and industry leaders together to explore how enterprises are turning decisions into coordinated action Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, is set to host Kinexions North America kicking off next week from June 1-3 at The Cosmopolitan of Las Vegas. The company’s flagship conference will bring together global supply chain, business and technology leaders for three days of product innovation, customer insights, and peer networking as Kinaxis continues to advance its focus on AI-driven decision making across the supply chain industry. This year’s event will spotlight how organizations are applying agentic AI and orchestration, moving beyond insight to execution, and increasingly from decisions to coordinated action. Speakers from global organizations including Merck, Bristol Myers Squibb, Unilever, British American Tobacco, Qualcomm, ExxonMobil, The Hershey Company, Scotts Miracle-Gro, and
Amadeus Redefines Travel Advertising to Help Brands Capture Demand Earlier28.5.2026 13:00:00 CEST | Press release
Developed in collaboration with Accenture, the AI-powered platform helps travel brands make smarter advertising decisions earlier and drive profitable demand through greater control, transparency, efficiency and performance. Amadeus today introduced the Amadeus Travel Advertising Platform at its Advertising Summit in Nice, France. Leveraging Accenture’s agentic framework for campaign execution, the platform outlines a new approach designed to help travel companies make faster, smarter advertising decisions based on where demand is forming — not just where it has already converted. Travel advertising has become increasingly complex, fragmented across channels and often driven by historical performance signals that arrive too late to capture emerging demand. As travelers plan trips across AI chatbots, search, social, metasearch, content platforms and OTAs long before booking, travel brands face rising acquisition costs and growing pressure to prove return on investment. The Amadeus Trave
Compass Pathways Elects Kathleen Tregoning to Board of Directors28.5.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access. “With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy, and patient access matters more
Alzprotect Announces FDA Clearance of IND for AZP2006 (Ezeprogind®) in Progressive Supranuclear Palsy (PSP)28.5.2026 12:28:00 CEST | Press release
IND enables initiation of U.S. clinical development in PSP Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526387210/en/ “FDA IND clearance is a pivotal step in our PSP program,” said Philippe Verwaerde, PhD, President & Chief science Officer. “We can now expand our clinical efforts in the U.S. to evaluate AZP2006’s potential to address PSP, a severe neurodegenerative disease with no approved disease-modifying therapies.” Dr. Artin Karapet, Chief Medical Officer, commented: “The FDA’s clearance of our IND for AZP2006 is a pivotal milestone, aligning U.S. and European regulatory pathways and enabling th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom